3521-62-8
Chemical Structure
Erythromycin estolate
- CAS No.: 3521-62-8
- Formula:C52H97NO18S
- Molecular Weight:1056.39
IUPAC Name: (2S,3R,4S,6R)-4-(dimethylamino)-2-(((3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-14-ethyl-7,12,13-trihydroxy-4-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3,5,7,9,11,13-hexamethyl-2,10-dioxooxacyclotetradecan-6-yl)oxy)-6-methyltetrahydro-2H-pyran-3-yl propionate dodecyl sulfate
InChIKey: AWMFUEJKWXESNL-JZBHMOKNSA-N
SMILES: CCCCCCCCCCCCOS(=O)(O)=O.CCC(O[C@H]([C@H](C[C@@H](C)O1)N(C)C)[C@]1([H])O[C@@H]2[C@H]([C@@H]([C@H](C(O[C@@H]([C@@](C)(O)[C@H](O)[C@@H](C)C([C@H](C)C[C@]2(O)C)=O)CC)=O)C)O[C@@]3([H])C[C@](C)([C@@H](O)[C@H](C)O3)OC)C)=O
Biological Activity: Erythromycin estolate is the Erythromycin (HY-B0220) derivative[1], is a macrolide antibiotic used in the treatment of a wide variety of bacterial infections. Erythromycin estolate causes several cases of liver injury which mostly include cholestatic hepatitis. Erythromycin estolate toxicity is related to its inhibitory effect on bile acid transport[2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Erythromycin estolate | 98.0% | Erythromycin estolate is the Erythromycin (HY-B0220) derivative, is a macrolide antibiotic used in the treatment of a wide variety of bacterial infections. Erythromycin estolate causes several cases of liver injury which mostly include cholestatic hepatitis. Erythromycin estolate toxicity is related to its inhibitory effect on bile acid transport. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Erythromycin estolate (Standard) | ≥98% | Erythromycin estolate (Standard) is the analytical standard of Erythromycin estolate. This product is intended for research and analytical applications. Erythromycin estolate is the Erythromycin (HY-B0220) derivative, is a macrolide antibiotic used in the treatment of a wide variety of bacterial infections. Erythromycin estolate causes several cases of liver injury which mostly include cholestatic hepatitis. Erythromycin estolate toxicity is related to its inhibitory effect on bile acid transport. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Lu X, et al. Integrated systems toxicology approaches identified the possible involvement of ABC transporters pathway in erythromycin estolate-induced liver injury in rat. Food Chem Toxicol. 2014 Mar;65:343-55. [Content Brief]
- [2]. Wang X, et al., Erythromycin Estolate Is a Potent Inhibitor Against HCoV-OC43 by Directly Inactivating the Virus Particle. Front Cell Infect Microbiol. 2022 Jul 7;12:905248. [Content Brief]
